Stockwinners Market Radar for December 06, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:33 EST Cathie Wood's ARK Investment bought 100K shares of Genius Sports today

20:32 EST Cathie Wood's ARK Investment bought 456K shares of Trade Desk today

20:01 EST Golden Heaven to enter operating lease framework with theme park in China - Golden Heaven "announced that it intends to enter into an operating lease framework agreement with a top-tier Chinese amusement group. The Group is a subsidiary of a prominent Chinese tourism group, ranking among China's top 30 national cultural enterprises and top 20 tourism groups. This Agreement is expected to mark a significant step in Golden Heaven's strategic business expansion efforts, and is aimed at enhancing Golden Heaven's market position by leveraging the Group's strong presence in the Chinese amusement park industry. Pursuant to the Agreement, that is presently under negotiation, the Group's theme park in Wuhan, Hubei Province in central China is expected to become the pilot leased park to the Company. The finalized operating lease rights, lease schedules and other terms of the Agreement will be settled with the ongoing negotiation."

19:50 EST Xos Inc trading halted, news pending

19:50 EST PAVmed trading halted, news pending

19:39 EST Knightscope CFO Mallorie Burak to step down to pursue other opportunities - Knightscope (KSCP) "announces that Apoorv S Dwivedi, a seasoned finance executive, has accepted the position of Executive Vice President and Chief Financial Officer of Knightscope, effective January 2024. With extensive finance and corporate strategy experience, Dwivedi most recently served as the Chief Financial Officer of Nxu (NXU). He joined the company in 2022 and helped to take it public on Nasdaq in the same year.Mallorie Burak, President and CFO, will be stepping down in early January 2024 to pursue other opportunities."

18:55 EST Amazon.com CEO: Consumers are still spending - In an interview on CNBC's Mad Money, Andy Jassy said consumers are still spending, but they are looking for bargains. "Whenever customers can trade down in price, they are wanting to do so." The consumables business growth rate has been very strong, he noted. Customers love getting items quickly, and increasingly, they can receive same day shipping, he added. He expects the price of Prime membership to increase "from time to time" as the value proposition increases. He continues to be "very bullish" on AWS for "2024 and beyond." He expects almost all of the generative AI spend to be in the cloud.

18:34 EST AerSale receives Boeing 737NG supplemental type certificate for 'AerAware' - AerSale (ASLE) "announced that the FAA has issued AerSale a Supplemental Type Certificate for "AerAware", the Company's revolutionary Enhanced Flight Vision System for the Boeing (BA) B737NG product line. This achievement marks the world's first commercial EFVS system2 to achieve a 50% visual advantage and the first large transport aircraft to be certified with a complete dual-pilot EFVS solution featuring a Head-Wearable Display. AerSale developed the AerAware certification program under license with The Boeing Company, which included access to necessary technical services, maintenance, and engineering data."

18:07 EST Anixa Biosciences' breast cancer vaccine shows positive Phase 1 results - Anixa Biosciences announced new and updated positive results from the Phase 1 clinical trial of its breast cancer vaccine. The trial is being conducted in collaboration with Cleveland Clinic with funding by a grant from the U.S. Department of Defense. The majority of patients developed ELISpot - T-cell - responses that met the rigorous protocol-specified definition of an immune response, with a measurable but lesser magnitude of response noted in the remaining patients. Among the doses studied, Dose Level 1 was determined to be a usable immunologic dose as well as the maximum tolerated dose. No significant side effects were observed, at the MTD, besides irritation at the sites of injection. Anixa and Cleveland Clinic plan to investigate additional intermediate dose levels and continue studying the vaccine's safety and immunologic effects in two additional patient cohorts. The first cohort, which opened for enrollment in August 2023, is evaluating the combination of the company's breast cancer vaccine with Keytruda in post-operative patients found to have residual disease following neoadjuvant chemo-immunotherapy. The second cohort will investigate the safety and immunologic effects of the vaccine in patients who are BRCA1, BRCA2, or PALB2 mutation positive and are planning prophylactic risk-reducing mastectomies. Anixa is the exclusive worldwide licensee to the novel breast cancer vaccine technology invented at Cleveland Clinic.

18:03 EST MediciNova granted new patent covering MN-166 for progressive MS in Europe - MediciNova has received a Notice of Decision to Grant from the European Patent Office for a pending patent application which covers the combination of MN-166 - ibudilast - and interferon-beta for the treatment of progressive multiple sclerosis, or MS. Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than October 2039.

17:52 EST PayPal names Suzan Kereere as President, Global Markets, EVP Alford to depart - PayPal Holdings (PYPL) announced the appointment of Suzan Kereere as President, Global Markets, effective January 1. She will have end-to-end accountability for leading PayPal's local businesses and growth strategies in the markets around the world where the company operates to ensure seamless execution and drive profitable growth. This includes overseeing the global sales and distribution of PayPal's products and services, helping to drive PayPal's position as a leading digital payment partner for businesses and consumers around the world...Kereere will join PayPal from Fiserv (FISV) where she currently leads Global Business Solutions, the company's merchant-focused offerings. Kereere previously served as Fiserv's Chief Growth Officer, leading strategy and business development to enhance customer value and accelerate growth across the enterprise. Peggy Alford, who currently serves as PayPal's Executive Vice President, Global Sales and Merchant Services, will transition from her current role at the end of the year and depart PayPal in January.

17:17 EST Chevron announces 2024 organic capex budget of $15.5B-$16.5B - The company states: "Chevron announced an expected organic capital expenditure range of $15.5B to $16.5B for consolidated subsidiaries and an affiliate capital expenditure budget of approximately $3 billion for 2024. Upstream spending in 2024 is expected to be about $14 billion. Of this planned expenditure, two-thirds is allocated to the United States, including approximately $6.5 billion to develop Chevron's U.S. shale and tight portfolio, of which around $5 billion is planned for Permian Basin development. About 25 percent of U.S. upstream capex is planned for projects in the Gulf of Mexico, including the Anchor project, which is expected to achieve first oil in 2024. Downstream capex is expected to be roughly $1.5 billion, with 80 percent allocated to the United States. Corporate and other capex is projected to be about $0.5 billion. Included in the upstream and downstream budgets is approximately $2 billion in lower carbon capex to lower the carbon intensity of traditional operations and grow new energy business lines. Chevron's Geismar renewable diesel expansion project is expected to start-up in 2024. Nearly half of affiliate capex is planned for Tengizchevroil's FGP / WPMP project in Kazakhstan and about a third is planned for Chevron Phillips Chemical Company, including the Golden Triangle Polymer Project and Ras Laffan Petrochemical Project. WPMP field conversion is forecasted to begin start-up in the first half of 2024."

17:11 EST Datadog CEO Pomel sells over $10M in company shares - Datadog CEO Olivier Pomel disclosed the sale of 85,637 shares of company stock at $117.36 per share on December 4, for a total transaction amount of $10,050,598.

17:10 EST Forward Air provides mid-quarter operational update through November 2023 - Forward Air provided key Expedited Freight operating statistics for the quarter-to-date period through November 2023. Weight per shipment increased 11.0%, revenue per shipment excluding fuel increased 2.6% and pounds per day increased 5.5%, all over the same period last year. Revenue per ton mile excluding fuel increased 1.8% and revenue per shipment excluding fuel increased 2.6% for the quarter-to-date period through November over the same period last year.

17:07 EST Patria Investments to acquire Credit Suisse's real estate business in Brazil - Patria Investments signed an agreement for the acquisition of Credit Suisse's Real Estate business in Brazil for total cash consideration of up to R$650M, around $130M. The transaction is structured with approximately $60M due upon completion of standard regulatory approvals, and up to an additional $70M incrementally conditioned to the successful shareholder approval process and transfer of underlying real estate funds. The funds are listed on the Brazilian stock exchange, and together would add up to $2.4B in assets under management to Patria's Real Estate platform. The funds represent permanent capital AUM with significant scale, with four funds each having a market capitalization over R$1.5B. Patria has now more than $3B in real estate assets under management as of November 2023.

17:05 EST Canadian National to aquire Iowa Northern Railway - CN announced that it has signed and closed an agreement to acquire Iowa Northern Railway, which operates approximately 275 track miles in Iowa connecting to CN's U.S. rail network. The transaction closed into an independent voting trust pending regulatory review of the transaction by the U.S. Surface Transportation Board. IANR serves upper Midwest agricultural and industrial markets covering many goods, including biofuels and grain. This transaction represents a meaningful opportunity to support the growth of local business by creating single-line service to North American destinations, while preserving access to existing carrier options. The terms of this transaction were not disclosed. An STB decision regarding the transaction is expected in 2024.

17:00 EST C3.ai falls 6% to $27.49 after Q2 results, cutting FY24 operating loss outlook

16:45 EST ChargePoint falls 2% to $2.00 after Q3 earnings miss

16:38 EST Braze jumps 5% to $59.20 after Q3 earnings beat, FY24 guidance raise

16:34 EST Asur reports total passenger traffic for November 2023 up 1.6% vs. last year - Asur reported passenger traffic for November 2023 reached a total of 5.8 million passengers, representing an increase of 1.6% compared to November 2022. Passenger traffic presented year-on-year increases of 3.8% in Mexico and 10.4% in Puerto Rico, while it decreased 9.0% in Colombia. Passenger traffic growth in Mexico and Puerto Rico was driven primarily by increases in international traffic of 4.6% and 27.8%, respectively, while domestic traffic increased 3.0% of 8.6%, respectively. Passenger traffic in Colombia was negatively affected by the suspension of operations of two local airlines from the beginning of 2023 which resulted in an 11.4% decline in domestic traffic while international traffic increased 2.0% year-on-year.

16:32 EST AbbVie to acquire Cerevel Therapeutics for $45.00 per share in cash, or $8.7B - AbbVie (ABBV) and Cerevel Therapeutics (CERE) announced a definitive agreement under which AbbVie will acquire Cerevel Therapeutics and its robust neuroscience pipeline of multiple clinical-stage and preclinical candidates with potential across several diseases including schizophrenia, Parkinson's disease, and mood disorders. The acquisition complements AbbVie's neuroscience portfolio, adding a wide range of potentially best-in-class assets that may transform standards of care across psychiatric and neurological disorders where significant unmet needs remain for patients. Under the terms of the transaction, AbbVie will acquire all outstanding shares of Cerevel for $45.00 per share in cash. The transaction values Cerevel at a total equity value of approximately $8.7B. The boards of directors of both companies have approved the transaction. This transaction is expected to close in the middle of 2024, subject to Cerevel shareholder approval, regulatory approvals, and other customary closing conditions. The proposed transaction is expected to be accretive to adjusted diluted earnings per share beginning in 2030.

16:30 EST AbbVie to acquire Cerevel Therapeutics for $45.00 per share in cash

16:27 EST Kilroy Realty says signed 520K sq. ft. of new or renewing leases quarter to date - Kilroy Realty "announced that it has signed approximately 520,000 square feet of new or renewing leases quarter to date, including approximately 400,000 square feet signed in November. Included in our November activity are two Bay Area leases signed for a combined 210,000 square feet to a Fortune 500 technology company and a highly regarded international law firm. Year-to-date office and life science leasing now totals approximately 1.3 million square feet, of which more than 50% are with new tenants. Average rents are approximately flat on a cash basis and up 15% on a GAAP basis over the prior leases. Catalyzed by a strong finish to the year, Kilroy is entering 2024 with average lease expirations of approximately 8.5% annually through 2026."

16:20 EST LianBio board determines not to pursue Concentra Biosciences proposal - LianBio announced that its Board of Directors unanimously determined not to pursue the unsolicited proposal from Concentra Biosciences, to acquire 100% of the equity of LianBio for $4.30 per share in cash, plus a contingent value right representing the right to receive 80% of the net proceeds payable from any license or disposition of LianBio's programs . After careful review and consideration, the Board unanimously concluded that the Proposal undervalues the Company and is not in the best interests of LianBio or its shareholders

16:18 EST Artivion appoints Lance Berry as CFO - Artivion appointed Lance Berry as the company's CFO, effective as of December 4. In this role, Berry joins Artivion's executive leadership team and replaces D. Ashley Lee, who will retire at the end of the year. Berry most recently served from January 2019 until November 2020 as the Executive VP, Chief Financial and Operations Officer of Wright Medical Group, until Wright was acquired by Stryker in November 2020. Before that, Berry served as the Senior VP, CFO for Wright from 2009 to 2018, spear-heading its merger with Tornier N.V. Additionally, Berry served as Wright's Vice President, Corporate Controller from 2002-2009. Berry also currently serves on the Boards of two public companies, Treace Medical Concepts and Vapotherm. Lee, who has served as the company's CFO since 2004, will retire after a transitional period. Lee will remain with Artivion in an advisory capacity to ensure a seamless transition.

16:17 EST Bristol Myers raises quarterly dividend to 60c from 57c per share - The dividend is payable on February 1, 2024, to stockholders of record at the close of business on January 5, 2024.

16:14 EST Option Care Health increases share repurchase program to $500M - Option Care Health announced that it anticipates completing the remaining $75M of repurchases in the fourth quarter under the original authorization. In addition, the company's board of directors approved an increase to its share repurchase program authorization from $250M to $500M. The program has no specified expiration date. The extent to which the company repurchases additional shares, and the timing of such repurchases, will depend upon a variety of factors, including market conditions, regulatory requirements, and other corporate considerations, as determined by the company's management.

16:12 EST Eastman Chemical raises quarterly dividend to 81c from 79c per share - The dividend is payable Jan. 5, 2024, to stockholders of record as of Dec. 18, 2023.

16:06 EST Compass Pathways: Psilocybin treatment results in bipolar II published in JAMA - Compass Pathways announced the publication of a paper in JAMA Psychiatry that demonstrates the potential for investigational COMP360 psilocybin treatment in treatment-resistant bipolar type II disorder . Results from the investigator-initiated open-label study were first presented at the Annual Meeting of the American College of Neuropsychopharmacology in 2022...There was no increase in the suicidality score based on the MADRS, no manic symptoms and no unexpected adverse events or difficulties with the dosing sessions reported throughout the study. The most common adverse event was headache reported by 4 out of 15 participants on the day of dosing, with symptoms resolving within 24 hours. "We're pleased that our study has been recognized and published by a highly regarded peer-reviewed journal," said Dr Scott Aaronson, MD, Chief Science Officer, Institute for Advanced Diagnostics and Therapeutics, Sheppard Pratt. "In what we believe to be the first study of its kind, we saw a significant number of patients experience relief from their bipolar II depression symptoms after a single 25mg dose of COMP360 psilocybin treatment. These findings need to be validated in larger studies."

16:03 EST Barnes & Noble Education affirms FY24 adjusted EBITDA view of about $40M - The Company is maintaining its guidance for fiscal year 2024 consolidated non-GAAP Adjusted EBITDA from Continuing Operations of approximately $40 million. The year-over-year increase is expected to be driven by growth in the Company's Retail Segment, primarily due to growth in the Company's BNC First Day programs, and the impact of the cost reduction actions the Company has executed and expects to continue to implement.

16:02 EST Marpai regains compliance with Nasdaq minimum bid price requirement - Marpai received notification from Nasdaq that it has regained compliance with Nasdaq's minimum bid price requirement and that the matter is closed.

15:03 EST AMD announces availability of Instinct MI300X accelerators - AMD (AMD) announced the availability of the AMD Instinct MI300X accelerators with "industry leading memory bandwidth for generative AI and leadership performance for large language model training and inferencing" as well as the AMD Instinct MI300A accelerated processing unit, which combines the latest AMD CDNA 3 architecture and "Zen 4" CPUs to "deliver breakthrough performance for HPC and AI workloads." Customers leveraging the latest AMD Instinct accelerator portfolio include Microsoft (MSFT), which recently announced the new Azure ND MI300x v5 Virtual Machine series, optimized for AI workloads and powered by AMD Instinct MI300X accelerators, AMD stated. "Several major OEMs also showcased accelerated computing systems, in tandem with the AMD Advancing AI event. Dell showcased the Dell PowerEdge XE9680 server featuring eight AMD Instinct MI300 Series accelerators and the new Dell Validated Design for Generative AI with AMD ROCm-powered AI frameworks. HPE recently announced the HPE Cray Supercomputing EX255a, the first supercomputing accelerator blade powered by AMD Instinct MI300A APUs, which will become available in early 2024. Lenovo announced its design support for the new AMD Instinct MI300 Series accelerators with planned availability in the first half of 2024. Supermicro announced new additions to its H13 generation of accelerated servers powered by 4th Gen AMD EPYC CPUs and AMD Instinct MI300 Series accelerators," AMD added.

14:23 EST Hulu on Disney+ rolls out its beta version to Bundle subscribers - A blog posting, Hulu on Disney+ Beta Launch, was released earlier, that said,in part: "Are you a fan of Loki on Disney+ and The Bear on Hulu? Well, soon, you'll be able to watch two of the most popular series on streaming without having to leave one app for another. Hulu on Disney+ rolls out its beta version to Bundle subscribers today before officially launching in the spring. It's an exciting next step for Disney and its streaming endeavors...Starting today, when Bundle subscribers open their Disney+ app, they will see a Hulu tile appear alongside the Disney, Pixar, Marvel, Star Wars, and National Geographic tiles..."I hope consumers realize that one Bundle subscription - which is competitively priced - can unlock the incredible original content, the blockbuster films that come from all our studios, and a 100 years' worth of stories from Disney+," Earley said. "Not to mention the amazing titles that come from Hulu Originals, FX, 20th Century Studios, Searchlight, and all of our amazing partners." Reference Link

14:11 EST Celsius says Dunkin win 'maybe opens doors' with 'retailers like Starbucks' - Asked during Morgan Stanley's Global Consumer and Retail Conference about some of the company's food service customer wins, Celsius Holdings (CELH) executives stated, according to a transcript of the event: I think that food service has obviously been a pretty big leap up for us this year. It was really non-existent for us prior to to the Pepsi (PEP) deal. It's tough to put a number on it because it's a bit of an unknown for us. I'd say it's early stages, but to be at 10% of Pepsi's revenues with us, that's pretty significant... So we do feel that Celsius has a bit of a different usage occasion than our our peers in the category. Jersey Mikes your referenced, we've got one into 2,000-plus locations there. That happened about six or eight weeks ago. The early data is encouraging there and the hope is that could be a proof of concept as we want to go into the other QSRs that Pepsi services, whether it's like I talked about Pizza Hut or some of the other establishments. And then, Dunkin Donuts, we went in to a number of their locations nationally, which I think is very interesting to go into a coffeehouse. They brought us in. They feel were incremental. We only went in with one SKU, hopefully with some more skews in there in the near future. But again, if that works out well, I think that really speaks to the expanded occasions with which Celsius offers and maybe opens doors even other retailers like Starbucks (SBUX)."

14:00 EST AMD, Nvidia both lower as AMD shows off AI accelerator chips - AMD (AMD), at its "Advancing AI" in-person and livestreamed event to launch the next-generation AMD Instinct MI300 data center GPU accelerator family and "highlight the company's growing momentum with AI hardware and software partners," predicted that the market for such products could grow to more than $400B in the next four years. At the event, CEO Lisa Su unveiled the MI300, which is taking aim at an industry leader Nvidia (NVDA). The new chip has more than 150B transistors and 2.4 times as much memory as Nvidia's H100, the current market leader, the company boasted. It also has 1.6 as much memory bandwidth, further boosting performance, AMD said. Companies using the processors will include Microsoft (MSFT) and Meta (META). In afternoon trading as AMD continues hosting the unveiling event, its shares are down fractionally to $117.81, while those of rival Nvidia (NVDA) are down about 1% to $459.92.

13:51 EST Bristol Myers reports approval of sNDA for Abecma in Japan - Bristol-Myers Squibb K.K. announced that the company has received manufacturing and marketing approval of the supplemental New Drug Application for an additional indication for Abecma, a B-cell maturation antigen-directed chimeric antigen receptor T cell immunotherapy, for patients with relapsed or refractory multiple myeloma who have received at least two prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody. Commenting on the approval, Makoto Sugita, Bristol Myers Squibb's head of R&D in Japan, said, "Multiple myeloma is an intractable disease with recurrent relapses that are difficult to cure with existing therapies. Treatment options for patients with RRMM are limited, and we are pleased that Abecma is the first CAR T cell therapy to be approved for earlier use as a treatment option to address the unmet needs of these patients. We remain committed to researching and developing innovative therapies to transform patient lives with serious diseases through science." Reference Link

13:24 EST Walmart 'confident as ever' in long-term framework - Walmart says that the "building blocks" of its long-term framework -- growing the top line at about 4% on a compounded annual basis over the next five years, with profits growing faster than that -- are going to happen over time.

13:16 EST Sunrun denials 'effectively lies,' Muddy Waters' Block says - Carson Block of Muddy Waters, who previously announced a short position in Sunrun (RUN), made the comment while being interviewed on CNBC from the Sohn London conference.

13:05 EST Webuy Global Ltd trading resumes

12:56 EST Pfizer granted orphan status for leukemia treatment - The FDA granted Pfizer orphan status for maplirpacept, its potential treatment of acute myeloid leukemia. Reference Link

12:35 EST Webuy Global Ltd trading halted, volatility trading pause

12:15 EST Deere boosts quarterly dividend 12c to $1.47 per share - The Deere & Company Board of Directors has declared a quarterly dividend of $1.47 per share payable February 8, 2024, to stockholders of record on December 29, 2023. The new quarterly rate represents an additional 12c per share over the previous level of $1.35.

12:06 EST Carvana, Phoenix Rising FC ink multi-year extension of partnership - Carvana announces the multi-year extension of its partnership with Phoenix Rising FC. In 2024, the Carvana kit sponsorship will expand to include Rising FC's Youth programs, which provide development opportunities, competitions, and a college advisory program for young athletes in the Phoenix and Prescott areas.

12:00 EST Box falls -9.7% - Box is down -9.7%, or -$2.58 to $24.11.

12:00 EST Yext falls -20.5% - Yext is down -20.5%, or -$1.44 to $5.58.

12:00 EST Phreesia rises 23.3% - Phreesia is up 23.3%, or $3.44 to $18.19.

11:52 EST McDonald's, Google Cloud announce strategic partnership - McDonald's (MCD) and Alphabet's (GOOGL) Google announced plans for a new multi-year, global partnership to connect Google Cloud technology across thousands of its restaurants worldwide. "This partnership is a significant step for McDonald's in advancing its restaurant technology platform to become the most sophisticated and productive in the industry. McDonald's plans to leverage a wide range of Google Cloud's hardware, data, and AI technologies to implement innovation faster and create even better experiences for its customers, restaurant teams, and employees," the restaurant company stated. "Google Distributed Cloud, a combined hardware and software offering, is planned to be deployed to thousands of McDonald's restaurants so they can leverage both cloud-based software applications and their own software and AI solutions locally on-site, as needed. With Google Cloud edge computing capabilities, McDonald's will be able to draw new insights into how equipment is performing, enact solutions that reduce business disruptions, and diminish complexity for crew so restaurant teams can focus on delivering amazing hospitality to customers. McDonald's will be the largest global foodservice retailer to use Google Distributed Cloud's new capabilities, with plans for thousands of restaurants to begin receiving their hardware and software upgrades next year. Through this new partnership, a dedicated Google Cloud team in Chicago will work in close proximity to McDonald's global innovation center, known as Speedee Labs. Together, they'll focus on applying generative AI across a number of key business priorities to power exciting new experiences for crew and customers, with McDonald's unmatched convenience and value," the company added. Reference Link

11:04 EST Ally Financial sees Q4 NIM 'a shade under' 3.20%

11:01 EST Northern Trust selected as custodian for NIC pension funds - Northern Trust has been selected by the Nebraska Investment Council to provide asset management and asset servicing solutions, including custody, portfolio analytics and securities lending, for its pension fund. The NIC is an independent state agency that manages $37.5B across 32 investment programs.

10:30 EST IXHL Stock trading resumes

10:15 EST Jupiter Acquisition Corp trading resumes

10:00 EST Cazoo falls -14.1% - Cazoo is down -14.1%, or -$5.72 to $34.78.

10:00 EST Yext falls -16.1% - Yext is down -16.1%, or -$1.13 to $5.88.

10:00 EST Phreesia rises 25.8% - Phreesia is up 25.8%, or $3.80 to $18.55.

09:57 EST BNY Mellon says Q4 NII trending modestly in right direction - Comments taken from the Goldman Sachs U.S. Financial Services Conference.

09:47 EST Box falls -10.3% - Box is down -10.3%, or -$2.74 to $23.95.

09:47 EST Asana falls -19.0% - Asana is down -19.0%, or -$4.43 to $18.88.

09:47 EST Phreesia rises 28.3% - Phreesia is up 28.3%, or $4.17 to $18.93.

09:41 EST Tandem Diabetes launches updated t:slim X2 insulin pump software with DexCom CGM - Tandem Diabetes (TNDM) announced the launch of updated t:slim X2 insulin pump software with Dexcom (DXCM) G7 Continuous Glucose Monitoring, or CGM, integration in the United States. Tandem's automated insulin delivery system with Control-IQ technology is the only AID option in the world to use Dexcom's latest CGM technology. Tandem will email instructions to all in-warranty t:slim X2 users in the United States to offer the option to add the new feature free of charge via remote software update. t:slim X2 pumps pre-loaded with the updated software are now shipping to new customers.

09:31 EST GT Biopharma: ISS, Glass Lewis recommend shareholders vote for proposed items - GT Biopharma announced that independent proxy advisory firms, Institutional Shareholder Services Inc. and Glass Lewis & Co., have recommended GT Biopharma stockholders entitled to vote at the company's 2023 Special Meeting of Stockholders to vote "FOR" Proposal items number 1 and 2. If approved, Proposal No. 1. will provide the company's Board of Directors with the option to implement a reverse stock split of the company's issued and outstanding common stock, if deemed necessary in the future, to maintain the company's listing on the Nasdaq Capital Market. "We are pleased that both ISS and Glass Lewis, the leading independent proxy advisory firms, support our Board's recommendation that stockholders vote "FOR" Proposal No. 1," said Michael Breen, Executive Chairman and Interim CEO of GT Biopharma, Inc. "Each stockholder's vote is important, so we strongly encourage each investor to follow the recommendations of ISS and Glass Lewis and vote "FOR" Proposal No. 1 as promptly as possible. Approval of Proposal No. 1 will provide the flexibility that will be essential, should we need to utilize this tool to maintain our Nasdaq listing. Confidence in our ability to maintain our Nasdaq listing will be an important complement to our ongoing efforts to enhance market awareness of the potential of our pipeline to improve the millions of lives and deliver value to our stockholders."

09:29 EST SuperCom announces new electronic monitoring contract - SuperCom announced that it has secured a new contract with a "prominent Kentucky-based service provider of electronic monitoring products and services." The company stated: "This contract marks another valuable step in SuperCom's expansion within the US, as well as progression in the deployment of its newest proprietary technologies: the new PureOne GPS bracelet and domestic violence monitoring solutions. Under this new contract, SuperCom will provide its cutting-edge PureOne GPS Tracking and PureProtect for DV Monitoring solutions. This initiative is part of a broader plan to enhance public safety and support rehabilitation efforts in communities across Kentucky."

09:24 EST McDonald's provides 2024 and long-term outlook and targets - McDonald's announced new growth targets to advance its Accelerating the Arches strategy. The company plans to increase its active loyalty user base to 250 million 90-day active users and deliver $45B in annual Systemwide sales to loyalty members by 2027. The company will expand its U.S. pilot of Ready On Arrival across its top six markets by 2025. Expects 30% of delivery orders to originate in its mobile app by 2027. TargetS expansion to 50,000 restaurants by the end of 2027. This will mark the fastest period of growth in Company history, with an expected run rate of 1,000 gross openings across the U.S. and International Operated Markets in 2027. McDonald's and Google Cloud announced a strategic partnership to connect the latest cloud technology and apply generative AI solutions across its restaurants worldwide. Beginning in 2024, the company will begin to deploy new, universal software that all McDonald's customer and restaurant digital platforms will run on - from the mobile app to loyalty and kiosks in store. The company expects a net restaurant unit expansion of nearly 2% of systemwide sales growth in constant currencies in 2024, and about 2.5% of systemwide sales growth in constant currencies in the average long-term beyond 2024. Expects operating margin in 2024 to be in the mid-to-high 40% range with continued expansion in the long term. Sees 2024 CapEx of $2.5B with sequential increases of about $300M-$500M each year through 2027.

09:20 EST Citi sees doing around $500M in share buybacks in Q4

09:19 EST Carnival on pace to achieve food waste reduction milestone - Carnival announced it has achieved a 38% reduction in food waste per passenger relative to its 2019 baseline, nearing its interim target to reduce food waste by 40% per person by 2025 on its path toward a 50% reduction by 2030. Less than a year since surpassing the previous 30% food waste reduction goal announced in its 2022 Sustainability Report, this performance signals continued momentum in the company's efforts to shrink its food print - an important element in the company's long-standing commitment to sustainable operations from ship to shore. To achieve its goals, Carnival Corporation has taken decisive measures onboard its ships to minimize unused food across every aspect of food preparation and dining services. In addition, the company has invested in advanced waste management technologies such as biodigesters to naturally break down and responsibly dispose of unused food. Together, these strategies support the company's responsible waste management practices and drive continuous momentum toward achieving its 2030 food waste reduction goal - part of its circular economy objectives to use fewer resources, produce less waste, and maximize recycling, while also helping to reduce the company's environmental impact and greenhouse gas emissions.

09:18 EST Overseas Shipholding announces 1st dividend since international unit spinoff - Overseas Shipholding Group announced that its Board of Directors has declared a cash dividend of 6c per share on its Class A Common Stock. "The dividend, the first dividend declared by OSG since the spinoff of its international division in 2016, " will be paid on January 4 to stockholders of record at the close of business on December 21...Under the share repurchase program, the Company may repurchase shares from time to time in open market transactions or in privately negotiated transactions. The timing and amounts of any purchases will be based on market conditions and other factors, such as price, in accordance with applicable laws. The program has no time limit, may be suspended, modified or discontinued at any time, and does not obligate OSG to purchase any particular amount of its common stock. The Company intends to fund the share repurchase program with excess cash.

09:17 EST SuperCom secures new electronic monitoring contract - SuperCom is pleased to announcethat it has secured a new contract with a prominent Kentucky-based service provider of electronic monitoring products and services. This contract marks another valuable step in SuperCom's expansion within the US, as well as progression in the deployment of its newest proprietary technologies: the new PureOne GPS bracelet and domestic violence monitoring solutions. Under this new contract, SuperCom will provide its cutting-edge PureOne GPS Tracking and PureProtect for DV Monitoring solutions. This initiative is part of a broader plan to enhance public safety and support rehabilitation efforts in communities across Kentucky.

09:16 EST LiveOne reports paid memberships increased 38% y/y - LiveOne announced an update for certain of its November 2023 memberships metrics. Added 57,000 New Paid Members in November with ARPU of $3.10+; Total Membership Currently at 3.4M+, a Year-Over-Year Increase of 30%.

09:11 EST NFT Gaming announces newest game launch, Battle Fleet AI - The NFT Gaming Company announced that the company has launched its third game, Battle Fleet AI for Android and iOS. The game is available to download in the Google Play Store and Apple App Store. To download the game, click here: Battle Fleet AI. "The NFT Gaming Company is extremely pleased to launch our third game as we continue to release games and develop content for Gaxos," said Vadim Mats, CEO of NFT Gaming Company. "Every game is a major milestone for NFTG and the Gaxos platform. We are proud of the progress we are making with artificial intelligence in our games as well as the optional Web 3.0 elements. Going forward, we anticipate releasing titles that casual gamers want and adding valuable assets to our business."

09:09 EST BriaCell is presenting posters on Bria-IMT at SABCS - BriaCell Therapeutics is presenting 3 posters including two today at the 2023 San Antonio Breast Cancer Symposium, SABCS, at Henry B. Gonzalez Convention Center, San Antonio, TX. Today's posters highlight the activation of cancer fighting immune cells by the Bria-IMT combination regimen that was identified using leading-edge technologies. These tools may be used to evaluate immune system responses to immunotherapy treatments, and perhaps to predict survival and clinical benefit in cancer patients treated with the Bria-IMT regimen. "Bria-IMT combination regimen with immune checkpoint inhibitors activated cancer-fighting CD8+ T cells turning "Cold" tumors "Hot" on ImmunoPET imaging." In summary, the use of leading technologies such as CD8 ImmunoPET imaging, peripheral blood tumor markers, and circulating cancer-associated cells demonstrate the therapeutic potential of the Bria-IMT combination therapy regimen. These findings support the use of this combination regimen in Phase 3 study. "Analysis of Antibody Response to SV-BR-1-GM Therapeutic Vaccine in Breast Cancer Patients Using Human Protein Microarrays: Potential Correlations with Therapy Response." Overall, BriaCell's data shows significant anti-tumor activity of its lead candidate, Bria-IMT in advanced metastatic breast cancer. Using innovative technologies, we believe that we have identified potential predictors of patients' survival following treatment with the Bria-IMT combination therapy regimen. We plan to further investigate these findings in our ongoing Phase 3 study in advanced metastatic breast cancer.

09:07 EST Scilex's ZTlido will be added as preferred agent to Medicaid PDL in two states - Scilex Holding announced that one Midwestern and one Southern State voted to add ZTlido as a preferred agent to their Medicaid Preferred Drug Lists, PDL, effective as of January 1, 2024. These changes have the potential to improve access to ZTlido for all eligible patients covered under Medicaid in these two states which will provide additional coverage to approximately 5.0 million lives.

09:06 EST INVO Bioscience merger partner NAYA Biosciences signs research partnership - NAYA Biosciences, which has recently signed a definitive merger agreement with INVO Bioscience to establish an expanded, publicly-traded life science company dedicated to increasing patient access to breakthrough treatments in fertility, oncology, and regenerative medicine, and ONK Therapeutics, a cell therapy company dedicated to developing the next generation of optimally engineered off-the-shelf natural killer - NK - cell therapies, have entered into a research partnership to evaluate combination therapy consisting of NAYA's FLEX-NK bispecific antibodies and ONK's optimally engineered NK cells. The merger has been unanimously approved by the board of directors of each company and is expected to close in Q1 2024. NAYA and ONK plan to assess several combination therapies in preclinical cancer models in 2024 prior to subsequently exploring initiating clinical trials. Both companies will share the costs of manufacturing and preclinical assessments.

09:04 EST Connexa Sports to start initial roll-out of Slinger AI Tennis app beta version - Connexa Sports confirmed that following a very positive consumer response to its request for beta testers for its Artificial Intelligence driven Slinger App for tennis, that the initial roll-out of the app's beta version will start later this week. Roll-out will be staged over several days with 250 tennis players per day being given free access to the App. The Slinger App, powered by Gameface, provides tennis players with access to analytics data through a sport specific, automated AI platform that analyzes and extracts data from uploaded player practice or match videos. Gameface's core analytic capabilities are delivered through a compatible single camera or smart phone, which facilitates scalable solutions for the tennis market without relying on specific hardware or camera types. Following completion of the beta testing, the Slinger App will launch to the market in February 2024. Initially users will be provided with a 'freemium' version with the plan to commence its estimated $10 per month or $100 per annum subscription service as new analytic features are added.

09:02 EST Rush Enterprises board approves $150M stock repurchase program - Rush Enterprises' Board of Directors approved a new stock repurchase program authorizing the Company to repurchase, from time to time, up to an aggregate of $150 million of its shares of Class A Common Stock, par value $0.01 per share, and/or Class B Common Stock, par value $0.01 per share. The Company also today announced that, concurrently with and as part of the stock repurchase program, it has purchased 1,500,000 shares of Class B Common Stock for an aggregate consideration of $65.3 million from W.M. "Rusty" Rush, the Company's Chairman of the Board, CEO and President. The transaction was funded with cash on hand. Mr. Rush advised the Company that the shares are being sold, in part, to repay a $40 million personal loan incurred by Mr. Rush with a balance of approximately $37 million that was secured by shares of the Class A Common Stock and Class B Common Stock owned by Mr. Rush as well as for financial diversification and tax planning purposes. The shares repurchased from Mr. Rush represent approximately 16.7% of the total shares of Class B Common Stock beneficially owned by Mr. Rush. After the transaction, Mr. Rush will continue to beneficially own 180,339 shares of Class A Common Stock and 7,493,809 shares of Class B Common Stock. The terms of the transaction were negotiated on behalf of the Company by a committee of independent directors of the Company's Board of Directors with the assistance of its independent legal and financial advisors, Baker Botts L.L.P. and Houlihan Lokey Capital, Inc.

08:57 EST British American Tobacco to take impairment charge mainly on U.S. brands - British American Tobacco (BTI) CEO Tadeu Marroco said: "Consistent with our vision to 'Build a Smokeless World', and in combination with the current macro-economic headwinds impacting the U.S. combustibles industry, in 2023 we will take an accounting non-cash adjusting impairment charge of around GBP 25B. This accounting adjustment mainly relates to some of our acquired U.S. combustibles brands, as we now assess their carrying value and useful economic lives over an estimated period of 30 years. Accordingly, we will commence amortization of the remaining value of our U.S. combustibles brands from January 2024. Building on our broad-based performance in 2023, I am clear that now is the right time to further invest to accelerate our transformation. We are making active investment choices to strengthen our U.S. business, accelerate innovation momentum in Heated Products globally, and enhance capabilities that support our strategic delivery. These investments will impact in 2024, and alongside continued macro-economic pressures in the U.S., we now expect growth in revenue and adjusted profit from operations of low-single digit on an organic1 basis at constant rates. We expect a progressive improvement to 3-5% revenue growth, and mid-single digit adjusted profit from operations growth on an organic1 basis at constant rates by 2026. We will continue to reward shareholders through our strong cash returns, including our progressive dividend, and, once the middle of our leverage range is reached, we will evaluate all opportunities to return excess cash to our shareholders. I am confident that the choices we are making today will drive our long-term success and deliver sustainable value for all of our stakeholders." Other publicly traded companies in the tobacco products space include Altria Group (MO), Imperial Brands (IMBBY) and Philip Morris (PM).

08:55 EST British American Tobacco now sees 2023 organic revenue at low end of guidance - British American Tobacco issued the following technical guidance for full year 2023: Global tobacco industry volume expected to be down circa 3%; Low end of 3-5% organic constant currency revenue growth; Strong New Category revenue growth with further improvement in category contribution alongside incremental investment; Mid-single figure constant currency adjusted diluted EPS growth, including a circa 2% transactional FX headwind; Translational FX is expected to be a circa 3% headwind on full year adjusted diluted EPS growth; Non-cash amortization charge will be treated as an adjusting item; Adjusted diluted EPS includes the divestment of our business in Russia/Belarus in September; Operating cash flow conversion close to 100%. Tadeu Marroco, Chief Executive, said: "In 2023 we continue to expect another year of delivery in line with our guidance. I am encouraged by the strong performances of Vuse and Velo, delivering strong volume led revenue growth, and increased profitability. As a result, we now expect New Categories to be broadly breakeven in 2023, two years ahead of our original target. In combustibles, while the U.S. macro-economic environment remains challenging, I am encouraged that our commercial plans are starting to deliver early signs of portfolio recovery. In AME and APMEA we expect to deliver another strong revenue and profit performance, driven by the strength of our well-balanced portfolio of global brands. Together, this performance demonstrates the benefit of our global footprint, and multi-category strategy. To accelerate the next phase of our transformation journey, we are now committing to 'Building a Smokeless World'. We will deploy our global multi-category portfolio to actively encourage smokers to 'Switch to Better' nicotine products, realising the multi-stakeholder benefits of 'A Better Tomorrow'."

08:48 EST Actelis Networks receives order for hybrid fiber-copper networking devices - Actelis Networks has received and has delivered a new order for multi-gigabit hybrid fiber-copper networking devices to help support the City of Everett's growing intelligent traffic management network.

08:42 EST Jaguar Health reports publication on quality of life for breast cancer patients - Napo Pharmaceuticals announced that the abstract for "More Than a Diagnosis: A Quality of Life Survey for Individuals with a Diagnosis or History of Cancer," an online, anonymous Napo-supported survey initiative of Advocates for Collaborative Education to shed light on the diverse and profound challenges faced by individuals living with a diagnosis or a history of cancer, is now available on the website for the December 2023 San Antonio Breast Cancer Symposium. Across a wide range of demographic subsets, including age, race, stage of cancer, and treatment modalities, 334 survey respondents with a history of breast cancer reported a decline in QoL scores precancer versus post-cancer. Physical and emotional well-being emerged as top priorities for most respondents, 47.9% and 27.5% respectively. Of 17 listed side effects, respondents cited fatigue, muscle/joint pain, and emotional distress as primary concerns, with sexual dysfunction and cognitive impairment ranking prominently. Forty-six percent reported severe to very severe emotional distress, but only 55% of those felt informed or well informed about the possibility of emotional distress. Among respondents, only 41% received a plan to address emotional distress. Many respondents felt unprepared for physical side effects. While 54% of individuals experienced diarrhea or fecal incontinence as a treatment side effect, 22% of affected individuals did not feel informed about the possibility of such side effects. Survey findings also highlight the consequences of treatments to manage side effects. Thirty-seven percent of respondents were prescribed treatment to address diarrhea and 100% of these patients reported additional side effects stemming from this supportive care, including nausea, constipation, and fatigue. Jaguar's poster outlining the design of the company's pivotal Phase 3 OnTarget trial for cancer therapy-related diarrhea and the neglected medical need of CTD will also be presented at SABCS on December 7th. The trial is evaluating the company's plant-based prescription drug crofelemer for prophylaxis of diarrhea in adult cancer patients with solid tumors receiving targeted therapy, with or without standard chemotherapy. The top line results of the study are forthcoming.

08:40 EST Verizon, Zebra Technologies launch device, software solutions - Verizon Business (VZ) and Zebra Technologies (ZBRA) announced the launch of Zebra mobile device and software packaged solutions designed to help Verizon Private 5G customers reap the benefits of their networks even faster. With Verizon Private 5G, Zebra's enterprise mobile computers and tablets will have more network capacity to work with, enabling instant and secure voice communication among groups of users in diverse commercial environments, from warehouses to manufacturing sites to industrial work zones and shipyards. "As a network provider, Verizon wants to make it easier for customers to get the devices and software they'll need to take full advantage of their private network as soon as possible," said Steve Szabo, Vice President of Business Products for Verizon Business. "Partnering directly with Zebra Technologies accelerates the timeline from adoption to implementation, giving critical days or weeks back to businesses that can get caught up in protracted cycles of getting operations up and running."

08:38 EST Lilium starts production of Lilium Jet - Lilium announces the start of production of the Lilium Jet, following the arrival of the first Lilium Jet fuselage at Lilium's final assembly line. In parallel, Lilium's world-class tier one suppliers are ramping up production of parts and systems for the Lilium Jet. Production of the Lilium Jet takes place at Lilium's state-of-the-art facilities in Wessling, Germany. Lilium's testing & manufacturing center, propulsion & aerostructures facility, final assembly building, and the newly constructed battery assembly building and logistics hub, where aircraft parts are readied for integration on the final assembly line, are all located alongside one another. In total, Lilium's facilities cover an area of 175,000 square-feet

08:38 EST Ramaco Resources increases cash dividend 10% to 13.75c per share - Ramaco Resources has approved an increase in the Class A dividend by 10% to 13.75c per share. The Q1 dividend is payable on March 15, 2024, to shareholders of record on March 1, 2024. The Board will announce the amount and timing of the Class B common stock dividend after completion of the company's year-end financials in February 2024.

08:36 EST Lead Real Estate sells 17-unit luxury condominium in Tokyo - Lead Real Estate announced that, on November 28, 2023, it completed the sale and delivery of a newly built single luxury income-producing condominium. The 17-unit property, Excelsior Meguromita, located in Meguro, Tokyo, is made from reinforced concrete and has four floors above ground and one basement floor. It has a building area of 10,232 square feet and land area of 3,810 square feet. Due to a confidentiality agreement with the seller, the seller and the sale price are not disclosed. There are no capital, personal, or business relationships between the Company and the seller, and there are no special interests between the Company and the seller.

08:35 EST IGC Pharma announces collaboration to integrate AI into clinical trials - IGC Pharma announced an Artificial Intelligence AI collaboration with Los Andes University's Center for Research and Training in Artificial Intelligence CINFONIA. The partnership aims to leverage Generative AI to analyze variations in disease signatures among patients, enabling IGC Pharma to identify individuals more likely to respond to treatment and subsequently accelerate the delivery of treatments to patients...These variables encompass neuropsychiatric scales, blood pressure, diet, and more intricate elements such as genetic markers and over 100 other biomarkers. The team has become implementing a deep learning algorithm to develop an adversary-based optimization methodology to enable the interpretation of non-linear relationships between these input variables and treatment outcomes, like efficacy and adverse events. The strategic integration of AI is an essential initiative for IGC Pharma as the Company is pursuing five assets developed to target Alzheimer's disease. These assets include IGC-AD1, TGR-63, LMP, IGC-1C, and IGC-M3, which are in different stages of development.

08:34 EST Alto Ingredients extends term loan commitment period - Alto Ingredients amended its $125M senior secured term loan facility with certain funds managed by Orion Infrastructure Capital to extend the commitment period for undrawn capital available under the term loan facility by one year to November 2024. No other material terms were changed.

08:33 EST MSA Safety wins $35M breathing apparatus contract with U.S. Air Force - MSA Safety announced it was awarded a $35M contract with the U.S. Air Force to provide its air base fire brigades with new respiratory protective equipment. The contract covers the supply of MSA's G1 Self-Contained Breathing Apparatus model along with related facepieces, chemical warfare component masks, and supplied-air respirator kits, which enable the SCBA to be used as a longer-duration airline device. The units will replace older model MSA air masks and will be used by U.S. Air Force fire brigades operating at U.S. air bases around the world. Production work in support of the U.S. Air Force units began this fall at the company's Murrysville, Pennsylvania manufacturing facility. The company expects deliveries to continue through year-end and extend into 2024.

08:32 EST NET Power and Lummus sign supplier agreement for heat transfer equipment - NET Power has signed a Strategic Supply Agreement with Lummus Technology to design and supply recuperative heat exchangers for NET Power's near-zero emissions power generation process. The HXR recovers energy from the turboexpander exhaust and air separation unit to reheat recirculated CO2. As the licensed NET Power HXR supplier, Lummus will provide HXR systems for NET Power's utility-scale power plants. Upon completing the Project Permian Front-End Engineering Design, NET Power intends to issue a purchase order to Lummus for its first utility-scale power plant in Texas.

08:31 EST OSI Systems awarded $5M contract - OSI Systems announced that its Optoelectronics and Manufacturing division has received orders totaling approximately $5M to provide electronic assemblies to a leading technology OEM. The company plans to use its operations in the United Kingdom to fulfill these orders.

08:29 EST Wallbridge Mining files preliminary base shelf prospectus - Wallbridge Mining Company has filed a preliminary short form base shelf prospectus with the securities regulatory authorities in each of the provinces and territories of Canada. The Shelf Prospectus, when made final and effective, will allow Wallbridge to offer from time to time over a 25-month period up to $50 million of equity, debt or certain other securities. The final base shelf prospectus is expected to be filed in the week of December 11, 2023. The Company currently has no plans to undertake a financing. The terms of future offerings, the intended use of the net proceeds resulting from such offerings and the terms of the Securities to be offered, if any, will be established at the time of any such offering and will be described in a prospectus supplement filed with the applicable Canadian securities commissions at the time of such an offering.

08:21 EST Cargo Therapeutics announces Scientific Advisory Board - CARGO Therapeutics announced the formation of a Scientific Advisory Board comprised of distinguished experts in cancer research, immunology, and CAR T-cell therapy. The SAB will be chaired by Robbie Majzner, MD, co-founder of CARGO and Director of the Pediatric and Young Adult Cancer Cell Therapy Program within the Departments of Pediatric Oncology and Medical Oncology at Dana Farber Cancer Institute and the Division of Hematology/Oncology at Boston Children's Hospital. The SAB will provide strategic counsel and critical expertise as CARGO advances its mission to develop the next generation of transformational CAR T-cell therapies. Members of the CARGO Scientific Advisory Board: Robbie Majzner, MD, co-founder of CARGO and Scientific Advisory Board Chair, and Director of the Pediatric and Young Adult Cancer Cell Therapy Program within the Departments of Pediatric Oncology and Medical Oncology at Dana Farber Cancer Institute and the Division of Hematology/Oncology at Boston Children's Hospital; Stephen Gottschalk, MD, Chair of the Department of Bone Marrow Transplantation and Cellular Therapy at St Jude Children's Research Hospital; Andras Attila Heczey, MD, Professor, Department of Pediatrics of Baylor College of Medicine, Section of Pediatric Hematology and Oncology; Marcela Maus, MD, PhD, Associate Professor at Harvard Medical School, the Paula O'Keefe Chair in Oncology, Director of Cellular Immunotherapy at Massachusetts General Hospital Cancer Center, Attending Physician in the Hematopoietic Cell Transplant and Cell Therapy Division of Oncology at MGH; Cameron Turtle, MBBS, PhD, Professor and CLEARbridge Chair in Cancer Immunotherapy in the Faculty of Medicine and Health at the University of Sydney; Clinical academic physician at Royal North Shore Hospital, Sydney, Australia

08:19 EST Organovo provides timing for release of FXR314 Phase 2 NASH results - Organovo Holdings will release final and complete data from a Phase 2a trial of FXR314 in non-alcoholic steatohepatitis patients by April 2024. The Company anticipates presentations at scientific meetings as well as publication in peer-reviewed journals. The release of this data will be the first public release of the completed clinical trial data. In an already reported interim analysis of about 60 patients after 16 weeks of treatment, FXR314 lowered liver fat content as demonstrated by a reduction in the median MRI-PDFF score of 28.6% in the 3 mg cohort and 26.9% in the 6 mg group compared with a reduction of only 1.5% in the placebo group. Post-hoc comparative assessment of relative liver fat reduction in the interim cohort found the decrease with 3 mg to be statistically significant compared to placebo. In a measure of activity in individual patients, FXR314 achieved greater than 30 percent liver fat reduction in 47 percent of patients in the 3 mg cohort and 35 percent in the 6 mg cohort, compared with 12 percent in the placebo arm. FXR314 was generally well-tolerated in this NASH population, with no treatment-related serious adverse events. All treatment-related AEs were mild-moderate with no apparent dose relationship. Mild-moderate pruritus was reported in one patient in the 3 mg cohort and one patient in the 6 mg cohort. No pruritus-related treatment discontinuations occurred. Organovo's current development program for FXR314 focuses on inflammatory bowel disease, where the drug's differentiated mechanism of action, as highlighted in Organovo's recently provided mechanism of action video, provides substantial promise that the drug's impact will strongly complement the biology of other successful drugs in ulcerative colitis and Crohn's disease. Organovo plans to begin enrollment for a proof-of-concept Phase 2 ulcerative colitis study in 1H 2024, with targeted completion in 1H 2025. The drug's additional promise in liver fibrosis and NASH makes it a strong candidate for development in that area through partnership collaborations with Organovo.

08:17 EST Clubhouse Media exploring implementation of AI on HoneyDrip.com - Clubhouse Media announced that HoneyDrip.com is engaging various AI consultants to explore the potential of using AI to support the back-end functions of the site and to enhance processes. The site has also seen month over month growth, continuing into November 2023. Honeydrip.com is a digital platform designed and wholly owned by CMGR with a focus on the empowerment of creators. The site allows creators to connect and engage with fans and monetize exclusive content. HoneyDrip.com has experienced rapid growth in four main categories during the month of November 2023 alone: Active performers on the site increased by 5% ; Content posts to be sold increased by 5%; Active users increased by 5%; Applications from creators wishing to join the site increased by 3%

08:17 EST Momentus in deal with CTS for transportation and orbital delivery services - Momentus signed a contract with CalgaryToSpace or CTS for transportation and orbital delivery services in 2025. CTS is the only student team in Calgary with the goal of building and operating a satellite in orbit. Momentus is contracted to fly CTS-SAT-1 - a scientific platform for two sophisticated payloads developed at the University of Calgary. The first is a Miniaturized Plasma Imager that will be used to study auroral arcs near the Earth's poles, developed by Dr. Johnathan Burchill. The second is a flexible carbon fiber boom manufactured using a patent-pending 3D printing technique, developed by PhD candidate Nick Elderfield...Momentus is currently booking rideshare and hosted payload customers on the SpaceX Transporter-11 mission targeted for no earlier than June 2024 and the SpaceX Transporter-12 mission targeted for no earlier than October 2024. Momentus provides its transportation and in-space services on either a deployer mounted directly to a Rideshare modular plate or a Vigoride Orbital Service Vehicle, depending on customer mission requirements. Momentus also offers its M-1000 satellite bus for customized and dedicated flights. .

08:14 EST Bionomics presents detailed data on validity, reliability of SUDS - Bionomics announced the presentation of data on the psychometric validity and reliability of Subjective Units of Distress Scale, SUDS, as an outcome measure in assessing anxiety in SAD clinical trials at the 2023 American College of Neuropsychopharmacology Annual Meeting taking place December 3 - 6 in Tampa, Florida. "We are excited to share the psychometric analysis we conducted of SUDS utilization in the Phase 2 PREVAIL trial of BNC210 in SAD, demonstrating it is a valid, reliable, and sensitive tool to assess anxiety," commented Spyros Papapetropoulos, M.D., Ph.D., President and CEO of Bionomics. "This presentation follows up the successful End-of-Phase 2 meeting we recently had with the U.S. Food and Drug Administration where we agreed on the plan for our registrational study of BNC210 in SAD, including the measurement of SUDS during a public speaking challenge as the primary efficacy endpoint." Key highlights from the poster presentation: BNC210 225 mg and 675 mg demonstrated reduced anxiety in patients with moderate to severe SAD in a public speaking challenge compared to placebo. BNC210 was well tolerated at both doses. Properties of the SUDS were evaluated to assess the SUDS's fit for measuring the reduction in self-reported anxiety severity provoked by a public speaking challenge in patients with SAD: Sensitivity: No floor or ceiling effects were observed in the use of the SUDS in the PREVAIL study indicating it is highly sensitive to change over the entirety of its range. Reliability: The reliability of the SUDS at 20- and 30-minutes post-challenge was very high for both the placebo and the full population. Validity: Baseline SUDS scores demonstrated good convergent validity when compared with State-Trait Anxiety Inventory scores.

08:13 EST Genasys announces new infrastructure protection orders for U.S. energy sector - Genasys announced sales to three companies in the nuclear energy and oil & gas sectors. The total value of the contracts is $750,000 and they include the Genasys Protect integrated platform and advanced acoustic devices. The systems will be deployed at sites in the central, southwestern, and southeastern United States. "Our intuitive, integrated platform provides robust and effective communication in high-stakes environments, "said Richard Danforth, CEO of Genasys, Inc. "These orders are indicative of the strong traction that Genasys systems and software are generating within the Critical Infrastructure Protection sector."

08:11 EST Bioventus agrees to nationwide contact with Aetna Medicare Advantage plans - Bioventus has agreed to a nationwide contract with Aetna Medicare Advantage plans. Beginning January 1, 2024, over 3 million Aetna Medicare Advantage plan members will have access to DUROLANE to treat knee osteoarthritis pain. DUROLANE, is a single-injection hyaluronic acid-based joint-fluid treatment for patients. DUROLANE will be one of two single-injection HA products under contract.

08:10 EST Brown-Forman sees FY24 organic net sales up 5%-7% - Sees FY24 capital expenditures $250M-$270M. Sees FY24 effective tax rate 21%-23%.

08:10 EST Byline Bancorp announces new 1.25M shares stock repurchase program - Byline Bancorp announced that its Board of Directors has approved a new stock repurchase program that authorizes the Company to repurchase up to 1.25m shares of the Company's outstanding common stock. The shares authorized to be repurchased represent approximately 2.9% of the Company's currently outstanding common stock. The new program will be effective January 1 and be in effect until December 31. Roberto R. Herencia, Executive Chairman and Chief Executive Officer of Byline Bancorp, Inc., stated, "The new share buyback authorization, which we believe is consistent with our disciplined approach, demonstrates our continued commitment to using this tool as part of our capital management strategy."

08:08 EST Cocrystal Pharma announces first-patient-in for Phase 2a study of CC-42344 - Cocrystal Pharma announces the achievement of first-patient-in for the Phase 2a human challenge clinical trial with CC-42344, an investigational new oral antiviral inhibitor for the treatment of pandemic and seasonal influenza A. This randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability, viral and clinical measurements of influenza A infection in subjects dosed with oral CC-42344 treatment. "There is an urgent need for new oral antivirals targeting pandemic and seasonal influenza that address drug resistance. CC-42344 was discovered using our proprietary structure-based drug discovery platform technology to inhibit the viral replication process. The data from this proof-of-concept clinical study will further validate CC-42344's novel mechanism of action," said Sam Lee, Ph.D., Cocrystal's President and co-CEO. "We expect to report topline data from this clinical trial in 2024."

08:08 EST SunOpta announces retirement of CEO Joseph Ennen, Brian Kocher named successor - SunOpta (STKL) announced the planned retirement of Joseph D. Ennen. After five years of dedicated service, Mr. Ennen will retire from SunOpta as its Chief Executive Officer and director on SunOpta's Board of Directors The Board has appointed Brian W. Kocher as the new Chief Executive Officer, effective January 2. In conjunction with this appointment, Mr. Kocher will also become a member of the Board. Mr. Kocher brings a wealth of experience in manufacturing intensive businesses in complex, multi-national organizations and has a strong track record of driving growth and productivity improvements. Brian previously served as President and Chief Executive Officer of both Calavo Growers (CVGW) a global avocado-industry leader and provider of convenient, ready-to-eat fresh food and Castellini Group of Companies, a nationwide produce distribution and supply chain service organization, as well as interim Chief Executive Officer of Chiquita. The Board is confident in Mr. Kocher's ability to lead SunOpta through its next phase of growth and his experience expanding margins and driving operational productivity will be incredibly valuable to the business. To ensure a seamless transition, which the Board believes is in the best interests of all stakeholders, Mr. Ennen will continue as an advisor to the Board and Mr. Kocher until April 1.

08:05 EST Journey Medical announces completion of pre-NDA meeting with FDA for DFD-29 - Journey Medical announced that the Company received the official meeting minutes from its pre-New Drug Application, NDA, meeting with the FDA for DFD-29 to treat rosacea in adults. DFD-29 is being developed in collaboration with Dr. Reddy's Laboratories Ltd. The purpose of the meeting was to discuss the 505(b)(2) NDA submission plan for DFD-29 for the treatment of inflammatory lesions and erythema of rosacea. During the pre-NDA meeting and in the official meeting minutes,the FDA agreed that the proposed data package is sufficient to support the NDA submission, which the Company continues to anticipate will occur around year-end of 2023. "We are encouraged by the pre-NDA meeting and the progress we have made towards our goal of securing the regulatory review and approval necessary to make DFD-29 available to patients. With all of the unique differentiators DFD-29 brings to the patient, it has the potential to become the best-in-class and the only oral, systemic therapy to address both inflammatory lesions and redness from rosacea, changing the treatment paradigm for this long-term inflammatory skin condition," said Claude Maraoui, Co-Founder, President and Chief Executive Officer of Journey Medical.

08:02 EST Phathom Pharmaceuticals announces FDA acceptance for filing VOQUEZNA NDA - Phathom Pharmaceuticals announced the FDA has accepted for review the company's NDA for VOQUEZNA as a daily treatment of heartburn associated with Non-Erosive gastroesophageal reflux disease, GERD, in adults. The FDA has assigned the application a standard 10-month review with a Prescription Drug User Fee Act, PDUFA, target action date of July 19, 2024. "Today marks an important step forward for Phathom Pharmaceuticals as we announce the FDA's acceptance for filing of our New Drug Application for VOQUEZNA as a daily treatment of heartburn for patients with Non-Erosive GERD," said Azmi Nabulsi, M.D., Chief Operating Officer at Phathom. "Non-Erosive GERD represents a substantial segment of the U.S. GERD population, affecting millions of individuals and impacting their quality of life. The supportive data in our regulatory application include the positive Phase 3 results from the investigational PHALCON-NERD-301 trial, along with a safety profile consistent with prior studies. We look forward to working closely with the FDA throughout the review process and if approved, expect to launch VOQUEZNA for this new indication in the third quarter of 2024."

07:41 EST Nextech3D.AI receives AI tool through technology transfer - Nextech3D.AI (NEXCF) has received a new AI-tool from its largest customer Amazon (AMZN), and is integrating the tool into its 3D model production pipeline. The AI tool will be used for speeding up the Quality Assessment for 3D models. By streamlining and automating the quality checks performed by the Company's team of quality assessors, it will ultimately reduce the time it takes, thereby boosting revenue and profits through enhanced productivity and efficiency.

07:40 EST Incannex to conduct Phase 2/3 trial of IHL-42X in patients with OSA - Incannex Healthcare provides the following update on its proprietary IHL-42X drug candidate. Obstructive sleep apnea is characterised by a narrowing or obstruction of the upper airway during sleep, which interrupts breathing resulting in decreased oxygen uptake and poor sleep quality. Incannex has designed IHL-42X, a combination of dronabinol and acetazolamide, for treatment of OSA. Results from IHL-42X proof-of-concept Phase 2 clinical trial :To demonstrate proof-of-concept for IHL-42X in the treatment of OSA, Incannex conducted a phase 2 clinical trial comparing three dose strengths of IHL-42X, low dose, medium dose and high dose, to placebo with regards to safety and efficacy in OSA patients. The trial was a four-period cross over study whereby every patient received each dose of IHL-42X and placebo for 7 days. The seven-day treatment periods were separated by 7-day washout periods to minimize any lasting effect of the treatment. On night seven of each treatment period, patients completed an overnight sleep study with polysomnography to assess AHI and other sleep parameters. The results of the sleep studies were compared to baseline values, captured prior to the start of treatment. Change in AHI relative to baseline was the primary endpoint for the study. The results of the proof-of-concept study confirmed the hypothesis that the combination of dronabinol and acetazolamide is effective at treating OSA. The average reduction in AHI compared to baseline for all three doses of IHL-42X, low, medium and high, reduced AHI to a substantially greater magnitude than placebo. When the difference in AHI relative to baseline was compared within each patient for the IHL-42X and placebo treatment periods the low dose was again most effective. The difference for all three doses compared to placebo was statistically significant. Further analysis of the within patient changes in AHI relative to baseline revealed that during the low dose treatment period 62.5% of patients had a reduction in AHI of greater than 50% and 25 % of patients experienced a reduction in AHI of greater than 80%. IHL-42X also improved oxygen desaturation index, sleep efficiency, and patient reported sleep quality. The results of the proof-of-concept Phase 2 clinical trial investigating IHL-42X in patients with OSA support the hypothesis that IHL-42X would be a safe and efficacious treatment. This gave Incannex the confidence to proceed with a multisite Phase 2/3 clinical trial further investigating safety and efficacy of IHL-42X in patients with OSA. The RePOSA study, a Phase 2/3 clinical trial investigating the safety and efficacy of IHL-42X in patients with obstructive sleep apnea To further assess the safety and efficacy of IHL-42X in patients with OSA, Incannex is conducting a Phase 2/3 clinical trial that will be conducted at fifty-five sites across the United States, Europe and other countries. The study has been named RePOSA, from Revealing the Efficacy of IHL-42X use in Patients with OSA. Reposa means to rest in Spanish, Portuguese and Italian. For this study, the high dose of IHL-42X from the proof-of-concept study has been dropped due to the psychoactive effects of THC at the 10 mg dose. In the RePOSA study the low dose is 2.5 mg dronabinol + 125 mg acetazolamide and the high dose is 5 mg dronabinol + 250 mg acetazolamide. The drug products being tested in the RePOSA study are representative of the to-be-marketed formulation developed by Incannex. In preparation for the study, Incannex conducted a pre-Investigational New Drug meeting with the US FDA to obtain feedback on the proposed clinical development strategy, safety and rationale for the IHL-42X drug product. This feedback was incorporated into the RePOSA Phase 2/3 study design and corresponding IND application. The IND was cleared by the FDA, and study may proceed notification was received in August 2023. The RePOSA study consists of two component studies. A four-week Phase 2 dose ranging study that will determine the optimal dose of IHL-42X based on safety and efficacy in OSA patients, and a 52-week Phase 3 factorial study that will compare the optimal dose of IHL-42X, as identified in Phase 2, to the component APIs, dronabinol and acetazolamide, at equivalent doses, as well as placebo. The study is designed to facilitate a seamless transition between Phase 2 and Phase 3, reducing downtime and accelerating the development timeline. The endpoints, inclusion/exclusion criteria and study procedures are the same across both component studies, which streamlines the transition process from Phase 2 to Phase 3. The target patient population is individuals aged 18 years or older with OSA who are intolerant, non-compliant or naive to PAP. The study will recruit at least 560 patients, with a total of 355 patients receiving IHL-42X over the course of the study. Start-up for the study is in progress with 22 sites selected in the US, 10 in Germany, and 1 in Finland.

07:35 EST Dragonfly Energy to supply battery systems for select Ameresco projects - Dragonfly Energy Holdings (DFLI) announced that beginning early next year the Company will be a supplier of battery systems for select projects for Ameresco (AMRC). Dragonfly Energy's Battle Born Batteries products will be included as an option in Ameresco's solar application builds across the various industries they serve including industrial, security, surveillance, traffic, telecom, oil & gas, utilities, agriculture, and more.

07:31 EST Danaher completes acquisition of Abcam - Danaher (DHR) announced it has completed its acquisition of Abcam (ABCM). As a result, Abcam has become an indirect wholly owned subsidiary of Danaher. Trading of Abcam ADSs on Nasdaq has been suspended.

07:24 EST Snowline Gold announces results from exploration holes on Rogue Project - SNOWLINE GOLD announced analytical results from additional exploration holes drilled on its Rogue Project in Canada's Yukon Territory. Hole V-23-061 returned 2.46 g/t Au over 519.6 m from surface, including 3.60 g/t Au over 265.6 m downhole, demonstrating a strong consistency of near-surface, multiple-gram-per-tonne-gold mineralization. Holes V-23-059 and V-23-060 were drilled within the southeast extension of the system and add dimensionality and consistency to known mineralization in that direction. Assays for more than 5,475 m of diamond drilling from Snowline's 2023 exploration efforts remain pending. "The Valley discovery on our 100%-owned, district-scale Rogue Project continues to demonstrate strong, continuous gold mineralization across a large area from surface," said Scott Berdahl, CEO & Director of Snowline. "Hole V-23-061 returned the strongest gold interval we've seen near surface in any hole to date, highlighting the favorable characteristics of the Valley system for efficient mining-namely strong, consistent mineralization with the highest grades beginning at or near surface in a topographically advantageous position. With December upon us, we have much to look forward to in terms of additional drill results, surface exploration results, advanced metallurgical testing and of course an aggressive exploration season ahead in 2024 on Valley and other targets across our greater than330,000 ha land position."

07:20 EST Microbix Biosystems announces initiation of normal course issuer bid - Microbix Biosystems announces the initiation of a Normal Course Issuer Bid program for the repurchase and cancellation of outstanding common shares. Specifically, the NCIB enables Microbix to repurchase up to 6,827,518 Common Shares, that number being approximately five percent of the 136,550,374 Shares outstanding as at December 1, 2023. Repurchases will be made through the facilities of the Toronto Stock Exchange over a 12-month period starting on December 8, 2023. The actual number of Shares which may be repurchased pursuant to the NCIB will be determined by management under applicable rules and policies. The NCIB has been approved by Microbix's Board of Directors and will be conducted in accordance with the applicable rules and policies of the TSX and Canadian securities laws, including TSX approval of Microbix's notice of intention to conduct a NCIB. Under the NCIB, Shares may be repurchased in open market transactions on the TSX, or by such other means as may be permitted by the TSX and applicable Canadian securities laws. Microbix will pay the prevailing market price at the time of its Share repurchases.

07:16 EST Bullfrog AI launches preclinical study on BF-114 in obesity - BullFrog AI Holdings announced the launch of a preclinical study to evaluate the efficacy of its drug candidate BF-114 in obesity. The study, which will be conducted in collaboration with Randy Seeley, Ph.D., the Henry King Ransom Endowed Professor of Surgery at Michigan Medicine, the academic medical center of University of Michigan, and Director of the Michigan Nutrition Obesity Research Center, is designed to evaluate the ability of BF-114 to modulate obesity in an established animal model and to elucidate the mechanism of action. The study is expected to be completed in the second quarter of 2024 and will complement internal activities that leverage the Company's AI platform to identify and address new pathways for targeting obesity and metabolic diseases. BF-114 is a siRNA molecule that targets Beta-II Spectrin and has shown promising results in animal models for obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis, all of which are areas of significant unmet medical need. Obesity affects over 40% of the US population and is associated with increased risk of heart disease and diabetes. Medical care costs for obesity-related health problems were estimated to be in excess of $170 billion in 2019.

07:15 EST Akoustis receives order from SATCOM for use of XBAW services - Akoustis Technologies announced that a leading commercial SATCOM company placed a new development order. Along with three existing customers, all utilize the Company's Process Design Kits and XBAW foundry process to address applications in Satellite Communications, Wi-Fi, Mobile, and Defense. Jeff Shealy, founder and CEO of Akoustis, stated, "With the release of our new XBAW synthesizer software and integration of the PDK download, we are empowering all levels of engineering to design BAW RF filters expanding above 10 GHz." Shealy continued, "As we continue to receive new orders for our foundry services, the XBAW PDK is a revolutionary development offering a comprehensive toolkit, which accelerates the design process and equips us to meet and exceed the demands of our existing customer base, keeping us at the forefront of RF advancements."

07:13 EST GXO Logistics conducting pilot of human-centric robot - GXO Logistics announced that it is conducting a proof-of-concept pilot for Agility Robotics' human-centric robot "Digit." The robot is being tested on logistics tasks at SPANX's facility in Flowery Branch, Ga., where GXO manages warehouse operations for the global womenswear brand's direct-to-consumer and in-store orders. "We're excited to take this pioneering step with Agility in the evolution of technology in warehouse operations," said Adrian Stoch, Chief Automation Officer, GXO. "As the industry leader in innovation, GXO works with global tech companies to develop and deploy technologies that will help our customers enhance safety, efficiency, productivity and employee engagement in their supply chain operations."

07:12 EST Rhythm says RM-718 demonstrated potential to reduce body weight, hyperphagia - Rhythm presented data from several pre-clinical studies showing that RM-718, a new, weekly, MC4R-specific agonist, demonstrated the potential to reduce body weight and hunger with a favorable safety profile. RM-718 is designed to be more highly targeted and MC1R sparing with the potential to not cause hyperpigmentation. The Company also showed data from pre-clinical studies demonstrating that RM-718 had no off-target cardiovascular effects in non-human primate studies. Rhythm also announced that it completed submission of a new investigational drug application for RM-718 to the FDA. The Company anticipates beginning Phase 1 in-human trials in the first half of 2024, including a multiple-ascending dose study in patients with hypothalamic obesity.

07:12 EST Upbound Group increases quarterly cash dividend 9% to 37c per share - Upbound Group announced that its board of directors has approved an increase of approximately 9% in the quarterly cash dividend to 37c for the first quarter of 2024. The dividend will be paid on January 9, 2024 to the company's common stockholders of record as of the close of business on December 19, 2023.

07:10 EST Tilray's Montauk Brewing expands across southeast, launches in Florida - Montauk Brewing, a subsidiary of Tilray Brands, announced expansion of its distribution into Florida. Montauk will bring two of its most popular styles, Wave Chaser India Pale Ale and Surf Beer Golden Ale, to the Sunshine State's burgeoning beer market. "We are incredibly excited to bring Montauk Brewing to Florida's vibrant beer scene. The Sunshine State is a great opportunity for Montauk, with new drinkers that we're eager to introduce to our coastal-inspired brews and a strong contingent of New Yorkers who are already fans," said Terry Hopper, VP Sales of U.S. Beer at Tilray.

07:09 EST Owens & Minor provides 2028 targets ahead of investor day - Owens & Minor will outline its strategy for delivering and expanding its profitability at its 2023 Investor Day event in Boston. The Company's 2028 financial targets include: revenue exceeding $12B; adjusted EBITDA exceeding $750M; adjusted EPS to exceed $3.50 with a CAGR of more than 20% and cumulative free cash flow between 2024-2028 of more than $1.3B.

07:04 EST Voyager Therapeutics selects development candidate for SOD1 program - Voyager Therapeutics announced that it has selected a lead development candidate for its superoxide dismutase 1-mutated amyotrophic lateral sclerosis gene therapy program. The Company anticipates filing an investigational new drug, IND, application with the Food and Drug Administration for the candidate in mid-2025. Voyager's SOD1-ALS lead candidate combines a highly potent siRNA construct to decrease the expression of SOD1 with an IV-delivered, blood-brain barrier-penetrant TRACER capsid. In a non-human primate study, the candidate demonstrated 73% reduction of SOD1 in cervical spinal cord motor neurons following a single intravenous dose in cynomolgus macaques. The candidate demonstrated robust knockdown of SOD1 across all levels of the spinal cord and motor cortex. Further, the candidate demonstrated an ability to transduce both neurons and astrocytes, two cell types thought to play an important role in ALS. Voyager expects to present additional data on the candidate at an upcoming scientific conference. In data previously shared at the 2022 American Society of Gene and Cell Therapy annual meeting, another Voyager SOD1-ALS preclinical candidate increased survival by a median of 152 days in a G93A mouse model, with survival in some animals exceeding 430 days. "Our SOD1-ALS program is one of several TRACER-powered gene therapy programs we expect to see advance to IND in 2025," said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. "We believe our development candidate could represent a significant advancement in the treatment of SOD1-mutated ALS by offering the potential for durable SOD1 knockdown with a single IV administration. SOD1 is a validated target, and we plan to utilize established cerebrospinal fluid and plasma biomarkers in early clinical studies to efficiently achieve potential proof of concept."

07:02 EST Canadian Solar's e-STORAGE to deliver 226 MWh DC storage to ENGIE in UK - Canadian Solar announced its majority-owned e-STORAGE will deliver 226 MWh DC of turnkey energy storage solutions to ENGIE in the UK (Scotland). e-STORAGE will construct the two energy storage projects, each with a capacity of 56.5 MW / 113 MWh DC in Cathkin and Broxburn, Scotland, UK. Both sites will be connected to the 33 kV network and are scheduled to reach grid connection in early 2025. e-STORAGE has signed an Engineering, Procurement, and Construction agreement with ENGIE for the construction of both sites. The two BESS projects will employ SolBank, a proprietary containerized energy storage solution using robust and high-cycle capacity lithium-iron-phosphate cells, active balancing battery management system and efficient thermal management system. e-STORAGE's SolBank provides customers with superior performance at the highest levels of safety. The Cathkin and Broxburn energy storage projects will support more than 40,000 homes and play a significant role in facilitating the UK's transition to net zero emissions by 2050.

06:54 EST Korn Ferry increases quarterly dividend 83% to 33c per share - Korn Ferry increased its regular quarterly cash dividend by 83% to 33c per share, payable on January 12, 2024 to stockholders of record on December 21, 2023.

06:47 EST Citi Trends adopts limited duration stockholder rights plan - Citi Trends announced that its Board of Directors has unanimously adopted a limited duration stockholder rights plan. The Rights Plan is intended to enable all stockholders to realize the full value of their investment in Citi Trends and will reduce the likelihood that any entity, person or group gains control of the company through open-market accumulation without paying all stockholders an appropriate control premium. The Rights Plan is also intended to provide the Board sufficient time to make informed judgments and take actions that are in the best interests of Citi Trends and all of its stockholders. The Board adopted the Rights Plan in response to one of its stockholders quickly accumulating a significant number of shares in the open market. The Rights Plan has not been adopted in response to any specific takeover bid or other proposal to acquire control of the company and is not intended to deter offers that are fair and otherwise in the best interests of the company and its stockholders. The Rights Plan is similar to stockholder rights plans adopted by other publicly held companies. Under the Rights Plan, the Rights generally would become exercisable only if any person (or group) acquires 16% (or 20% for certain passive investors) or more of Citi Trends' outstanding common stock, except that any person or group who currently owns the triggering percentage or more may continue to own such shares of common stock. However, any owner of the relevant triggering percentage or more may not, subject to the terms of the Rights Plan, acquire any additional shares without triggering the Rights Plan. The Rights Plan does not aggregate the ownership of stockholders "acting in concert" unless they have formed a group, or the shares would otherwise be aggregated, under applicable securities laws. The Rights Plan expires on December 4, 2024, unless earlier redeemed, exchanged or amended. The Board intends to submit the Rights Plan to stockholders for ratification at the company's upcoming Annual Meeting of Stockholders and to terminate the Rights Plan if the proposal to ratify the Rights Plan is not approved at that meeting.

06:35 EST Bill to reduce global workforce by 15%, close Sydney, Australia office - In a regulatory filing on Tuesday, BILL Holdings announced that it will reduce its global workforce by approximately 15%, close its office in Sydney, Australia, allocate resources to its key business priorities in service of small and midsize businesses and focus on improving the profitability of its core business. The company estimates that it will incur charges of approximately $29M-$35M in connection with the Restructuring, primarily consisting of cash expenditures for severance payments, employee benefits and related costs, in addition to non-cash charges for stock-based compensation expense. The company expects that the majority of these charges will be incurred in the three months ending December 31, 2023, and substantially all of these charges will have been incurred by June 30, 2024.

06:34 EST Waters inaugurates new Global Capability Center in India - Waters inaugurated its new Global Capability Center, or GCC, an investment to accelerate technology adoption, innovation, digital transformation, and business efficiencies through a concentrated hub of talent that will operate across the Waters global enterprise. The Waters India GCC is in a newly built facility in Bengaluru's RMZ Ecoworld technology park, a WELL and LEED Platinum-certified campus. The new $16M workspace will employ 300+ for roles that were formerly outsourced to various outside service providers and will transform into an India-based global hub designed to in-source talent, accelerate technology adoption, and drive technological innovation.

06:32 EST NGL Energy Partners announces open season for Grand Mesa Pipeline - NGL Energy Partners announced that a binding open season will start December 6 2023 at 8:00 am Central Daylight Time for its wholly owned affiliate Grand Mesa Pipeline's crude oil pipeline. This open season will close on January 5, 2024 at 5:00 pm Central Daylight Time. Grand Mesa provides takeaway capacity for crude oil producers in the Denver-Julesburg Basin. It originates in Weld County, Colorado and extends approximately 550 miles southeast to NGL Crude Cushing, LLC's storage terminal at Cushing, Oklahoma. NGL held open seasons in 2016 and in 2021 seeking commitments from shippers interested in shipping on Grand Mesa's pipeline system. NGL is holding the current open season to contract available capacity on the Grand Mesa pipeline at a discounted rate. The total capacity being offered in this open season is 40,000 barrels per day for delivery into the Cushing hub.

06:31 EST Exxon Mobil pursuing more than $20B in lower emissions opportunities, up $3B

06:30 EST Exxon Mobil increasing pace of share repurchases to $20B per year through 2025

06:06 EST EnCore Energy enters master transaction agreement with Boss Energy - EnCore Energy announced that it has entered into a master transaction agreement with Boss Energy, which, upon completion, will result in the sale of a 30% ownership interest in EnCore's Alta Mesa project to Boss Energy for $60M, an investment of $10M into enCore common shares by Boss Energy, a loan of up to 200,000 pounds U3O8 for enCore's commercial use over the next year, and the formation of a strategic collaboration on the use and joint development of enCore's proprietary Prompt Fission Neutron, or PFN, technology for uranium exploration and production. The transaction, expected to be completed in February 2024, provides EnCore with the financial capacity to significantly accelerate its uranium production pipeline across South Texas through the development of multiple satellite operations. In addition, the transaction paves the way for expansion, consolidation and development of enCore's Dewey Terrace and Dewey-Burdock projects straddling the Wyoming-South Dakota border and enables the Company to quicken development of its Gas Hills project in Wyoming.

06:05 EST Twitch to shut down streaming platform in South Korea - Video streaming service Twitch will shut down its services in South Korea on February 27, 2024, CEO Dan Clancy said in a blog post. Clancy said that "ultimately, the cost to operate Twitch in Korea is prohibitively expensive and we have spent significant effort working to reduce these costs so that we could find a way for the Twitch business to remain in Korea. First, we experimented with a peer-to-peer model for source quality. Then, we adjusted source quality to a maximum of 720p. While we have lowered costs from these efforts, our network fees in Korea are still 10 times more expensive than in most other countries. Twitch has been operating in Korea at a significant loss, and unfortunately there is no pathway forward for our business to run more sustainably in that country." Twitch is owned by Amazon. Reference Link

06:01 EST Yum! Brands' KFC to acquire over 200 KFC restaurants from EG Group - Yum! Brands' KFC Division announced that it has entered into a definitive agreement to acquire over 200 KFC restaurants from EG Group, the company's largest KFC franchisee in the UK and Ireland. The transaction represents a significant opportunity to accelerate KFC's growth strategy in the large and growing UK and Ireland chicken market, with high average unit volumes and robust margins. The experienced KFC UK management team, which currently operates a leading set of 50 high-performing company-owned restaurants across the UK and Ireland, will focus on delivering an enhanced customer experience and deploying its digital strategy to drive higher unit volumes and market share growth. KFC UK and Ireland has a strong track record of consistent growth that has continued this year, with system sales up 7% and same-store sales up 5% across its 1,040 restaurants. Since 2018, KFC has opened 200 new restaurants across the UK and Ireland, and with the market demonstrating renewed potential since the start of 2023, KFC has previously announced plans to open a further 500 restaurants across the market by 2030. Once completed, all of EG's KFC UK and Ireland business - over half of which is made up of drive-thrus - and 7,800 team members will come under KFC UK and Ireland management. This acquisition will cement the compelling leadership position that KFC has built across the UK and Ireland over many years - allowing the business to drive growth and gain market share. Yum! anticipates finalizing the transaction by the end of the first half of 2024. The transaction will be funded from Yum!'s cash flows and is expected to have an immaterial impact on Yum!'s 2024 financial results. With this acquisition, Yum! Brands maintains its highly efficient asset-light strategy including a global restaurant base that's predominately franchisee-owned.

05:20 EST UMC reports November revenue NT$18.79M, down 16.67%

05:12 EST Aurora Mobile announces one-for-twenty reverse ADS split - Aurora Mobile announced that it will change the effective date of its change to the ratio of its American depositary shares. On November 30, Aurora Mobile announced that it intended to change the ratio of its ADSs to its Class A common shares, par value US$0.0001 per share, from three ADS representing two Class A common shares to three ADS representing forty Class A common shares effective on or about December 6. Aurora Mobile will change the ratio of its ADSs effective December 11, U.S. Eastern Time. The ADS ratio change will have the same effect as a one-for-twenty reverse ADS split for Aurora Mobile's ADS holders. The ADS ratio change will have no impact on Aurora Mobile's underlying Class A common shares, and no Class A common shares will be issued or cancelled in connection with the ADS Ratio Change. On the effective date, holders of the ADSs will be required to surrender and exchange every twenty ADSs then held for one new ADS.